EQRx — FY2021 Earnings Presentation
12 slides from EQRx's earnings presentation, Mar 23, 2022
Slide 1: Q4 & FY 2021 Financial Results, Business Update
©EQRx 2021 | REMAKING MEDICINE v v v v5 March 23, 2022, 8:00am ET Conference Call and Webcast Q4 & FY 2021 Financial Results, Business Update ©EQRx 2022 | REMAKING MEDICINE
Slide 2: Disclaimer
©EQRx 2021 | REMAKING MEDICINE DISCLAIMER This presentation (this “Presentation”) relates to EQRx , Inc. (together with its subsidiaries, “ EQRx ”). EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lo wer prices. Launch
Slide 3: Our Mission: Improve health for all with great, innovative, affordable medicines
©EQRx 2021 | REMAKING MEDICINE IMPROVE HEALTH FOR ALL WITH GREAT, INNOVATIVE, AFFORDABLE MEDICINES OUR MISSION
Slide 4: Today's key takeaways
©EQRx 2021 | REMAKING MEDICINE Today’s 3 key takeaways Expanding the Global Buyers Club; goal to have MOUs with payers that cover 350M lives by the end of 2022 $1.7B in cash and cash equivalents*, with expected runway into 2025 Expect first submissions to be ex - US in 2H 2022 for lead programs; con
Slide 5: Aumolertinib | 3rd-generation EGFR TKI
©EQRx 2021 | REMAKING MEDICINE 5 Aumolertinib | 3rd - generation EGFR TKI Phase 3 trial in patients with 1L EGFR+ NSCLC* demonstrated statistically significant PFS benefit , with the potential to mitigate EGFR wild - type mediated toxicities Completed PK study conducted in the US and New Zealand in
Slide 6: Sugemalimab | anti-PD-L1 antibody
©EQRx 2021 | REMAKING MEDICINE 6 Sugemalimab | anti - PD - L1 antibody Phase 3 Stage IV NSCLC trial demonstrated statistically significant PFS and OS benefit on pre - specified analyses, regardless of tumor pathologic subtype or PD - L1 expression levels Phase 3 Stage III NSCLC trial demonstrated st
Slide 7: Pipeline with 10+ programs in clinical stage of development
©EQRx 2021 | REMAKING MEDICINE 7 Pipeline with 10+ programs, 5 in clinical stage of development ONCOLOGY & IMMUNE - INFLAMMATORY DISEASES Undisclosed Program Undisclosed Program Undisclosed Program Undisclosed Program Undisclosed Program $500B GLOBAL SPECIALTY SPEND ADDRESSED $100B Nofazinlimab PD -
Slide 8: Selectively add to our portfolio: catalog of medicines criteria
©EQRx 2021 | REMAKING MEDICINE 8 Selectively add to our portfolio x Address a drug class of high - cost burden to patients and society and deliver meaningful value to the members of the Global Buyers Club x Equally good or better medicine x Areas where there are known, clear and causal mechanisms of
Slide 9: Continuing to advance Global Buyers Club
©EQRx 2021 | REMAKING MEDICINE REMAKING MEDICINE DISTRIBUTION PARTNERSHIP Pharmacy benefit manager & national payer Single payer system Regional payers Integrated delivery network GLOBAL BUYERS CLUB 180M+ LIVES Continuing to advance Global Buyers Club Goal to have 350M total covered lives by the end
Slide 10: $1.7B in cash with expected runway into 2025; 2022 spend guidance
©EQRx 2021 | REMAKING MEDICINE Very selectively add to our portfolio where we can: $1.7B in cash and cash equivalents*, with expected runway into 2025 • Disciplined use of capital and control of spend • Opportunity to further shape our portfolio and deliver value for patients and our Global Buyers C
Slide 11: Expected milestones for 2022
©EQRx 2021 | REMAKING MEDICINE Expected milestones for 2022 • Submit aumolertinib and sugemalimab ex - US in 2H 2022 • Updates on regulatory approach and timelines when available • Initiate comparative studies • $400M or less in cash outflows for 2022 • New partnerships with unique types of payers •
Slide 12: This is NEW PHARMA
REMAKING MEDICINE This is NEW PHARMA